Literature DB >> 20202795

Is perseveration uniquely characteristic of schizophrenia?

Rachel N Waford1, Richard Lewine.   

Abstract

Evidence for the existence of categorically distinct disorders such as schizophrenia, bipolar disorder, and major depression is mixed: neuropsychological impairments may be similar in schizophrenia and bipolar disorder; schizophrenia and major depression show similar neuropsychological and frontal lobe disturbances; and overlap in biochemical anomalies among the disorders has also been reported. Interestingly, there are very few studies that directly compare all diagnoses. The present study compares cognitive perseveration in these three diagnostic groups using the Wisconsin Card Sorting Task (WCST) to examine performance across patients with schizophrenia (n=143), bipolar disorder (n=25) and major depression (n=21). Individuals used in this sample were 18-45 years old at time of testing to eliminate confounds of aging. Sex ratios within each diagnostic group are comparable to those of the national population. Univariate analyses examining diagnostic group and percent perseverative error revealed no significant differences in WCST performance across the diagnostic groups. Examination of clinical variables in the sample of individuals with schizophrenia revealed that perseveration is related to negative symptoms and depressive symptoms in young adults. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20202795     DOI: 10.1016/j.schres.2010.01.031

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  7 in total

1.  Infusions of Nerve Growth Factor Into the Developing Frontal Cortex Leads to Deficits in Behavioral Flexibility and Increased Perseverance.

Authors:  Sagar J Desai; Brian L Allman; Nagalingam Rajakumar
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

2.  Effects of ketamine on context-processing performance in monkeys: a new animal model of cognitive deficits in schizophrenia.

Authors:  Rachael K Blackman; Angus W Macdonald; Matthew V Chafee
Journal:  Neuropsychopharmacology       Date:  2013-05-10       Impact factor: 7.853

3.  Intra-accumbens injection of a dopamine aptamer abates MK-801-induced cognitive dysfunction in a model of schizophrenia.

Authors:  Matthew R Holahan; Dan Madularu; Erin M McConnell; Ryan Walsh; Maria C DeRosa
Journal:  PLoS One       Date:  2011-07-13       Impact factor: 3.240

4.  Signal attenuation as a rat model of obsessive compulsive disorder.

Authors:  Koral Goltseker; Roni Yankelevitch-Yahav; Noa S Albelda; Daphna Joel
Journal:  J Vis Exp       Date:  2015-01-09       Impact factor: 1.355

5.  Placing Cognitive Rigidity in Interpersonal Context in Psychosis: Relationship With Low Cognitive Reserve and High Self-Certainty.

Authors:  Helena García-Mieres; Judith Usall; Guillem Feixas; Susana Ochoa
Journal:  Front Psychiatry       Date:  2020-11-26       Impact factor: 4.157

6.  Progressive changes in descriptive discourse in First Episode Schizophrenia: a longitudinal computational semantics study.

Authors:  Maria Francisca Alonso-Sánchez; Sabrina D Ford; Michael MacKinley; Angélica Silva; Roberto Limongi; Lena Palaniyappan
Journal:  Schizophrenia (Heidelb)       Date:  2022-04-12

7.  Effects of Ginkgo biloba extract EGb 761® on cognitive control functions, mental activity of the prefrontal cortex and stress reactivity in elderly adults with subjective memory impairment - a randomized double-blind placebo-controlled trial.

Authors:  Stefanie M Beck; Hannes Ruge; Christoph Schindler; Martin Burkart; Robert Miller; Clemens Kirschbaum; Thomas Goschke
Journal:  Hum Psychopharmacol       Date:  2016-05       Impact factor: 1.672

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.